Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
IsraelIPO:
20 November 2015Website:
http://purple-biotech.comNext earnings report:
22 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 20:58:57 GMTDividend
Analysts recommendations
Institutional Ownership
PPBT Latest News
REHOVOT, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it has entered into definitive agreements for the exercise of certain existing warrants to purchase an aggregate of 5,633,509 American Depositary Shares (ADSs), each representing 10 ordinary shares, having original exercise prices ranging from $1.25 to $20.00 per ADS, originally issued by Purple Biotech in October 2023, June 2020, January 2019 and June 2018, at a reduced exercise price of $0.36 per ADS. The issuance and/or resale of the ADSs issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form F-3 (File Nos. 333-268710, 333-235327 and 333-215037). The offering is expected to close on or about July 2, 2024, subject to satisfaction of customary closing conditions.
REHOVOT, Israel, June 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class oncology therapies that overcome tumor immune evasion and drug resistance, today reported additional positive interim data from its randomized, controlled, open label, multicenter Phase 2 study (NCT 04731467) of CM24, in combination with Bristol Myers Squibb's immune checkpoint inhibitor nivolumab and standard of care (SoC) chemotherapy, in second-line metastatic pancreatic ductal adenocarcinoma (PDAC). These results suggest that serum MPO may be a predictive biomarker for survival in the CM24+Nivolumab + Nal-IRI/5FU/LV arm. The company also announced that it will host a virtual KOL event on Thursday, July 11, 2024 at 10:30 AM ET to discuss the results in detail. To register for the event, click here.
Purple Biotech Ltd. Sponsored ADR (PPBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
Purple Biotech (NASDAQ: PPBT ) just reported results for the fourth quarter of 2023. Purple Biotech reported earnings per share of -19 cents.
What type of business is Purple Biotech?
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
What sector is Purple Biotech in?
Purple Biotech is in the Healthcare sector
What industry is Purple Biotech in?
Purple Biotech is in the Biotechnology industry
What country is Purple Biotech from?
Purple Biotech is headquartered in Israel
When did Purple Biotech go public?
Purple Biotech initial public offering (IPO) was on 20 November 2015
What is Purple Biotech website?
https://purple-biotech.com
Is Purple Biotech in the S&P 500?
No, Purple Biotech is not included in the S&P 500 index
Is Purple Biotech in the NASDAQ 100?
No, Purple Biotech is not included in the NASDAQ 100 index
Is Purple Biotech in the Dow Jones?
No, Purple Biotech is not included in the Dow Jones index
When does Purple Biotech report earnings?
The next expected earnings date for Purple Biotech is 22 August 2024